

Supplementary Materials for "Meta-Analysis of Breast Cancer Risk for Individuals with PALB2 Pathogenic Variants"

Thanthirige Lakshika M. Ruberu, Danielle Braun, Giovanni Parmigiani, and Swati Biswas

Summary of the Meta-Analysis Method

Our meta-analysis approach proposed in Ruberu et al. (2024) can integrate different types of risk measures such as age-specific penetrances, OR, RR, and SIR accounting for uncertainties involved in such a synthesis. Specifically, we assume that, irrespective of the reporting modality, the cumulative penetrance $F_s(t|\kappa_s, \lambda_s)$ at age t for study s is given by the c.d.f. of a Weibull distribution with shape parameter κ_s and scale parameter λ_s . For each modality, we assume that the reported risk estimate follows a normal distribution whose mean is expressed in terms of Weibull distribution (and hence its parameters κ_s and λ_s) and variance is fixed at what was reported by the study. This enables expressing the likelihood for each study in terms of penetrance parameters as in Marabelli et al. (2016). Furthermore we assume that studies have no patient overlap and are conditionally independent given the study-specific parameters specified below. Our full likelihood is then simply the product of likelihoods from each study.

We employed a Bayesian hierarchical model where the κ_s and λ_s parameters are assumed to follow gamma priors with their parameters having uniform hyper-priors each with pre-specified lower and upper limits (l, u) . Specifically, we used the following hierarchical priors: $\kappa_s \sim \text{Gamma}(a, b)$, $\lambda_s \sim \text{Gamma}(c, d)$, where a and c are shape parameters, b and d are scale parameters, and $a \sim \text{U}(7.5, 27.5)$, $b \sim \text{U}(0.15, 0.25)$, $c \sim \text{U}(43, 63)$, and $d \sim \text{U}(1.32, 2.02)$. To choose the limits of the uniform distributions, our main consideration was that the penetrance values (from Weibull distributions) at ages 20-80 resulting from those choices ensured a wide coverage while avoiding unrealistic values. For instance, a penetrance value of 90% at age 20 is deemed unrealistic.

We started by fixing the limits (l, u) for each hyper-parameter, generated 50 values for a , b , c , and d , then using those values simulated 50 κ_s and λ_s , and computed penetrance values from resulting Weibull(κ_s, λ_s) distributions. We repeated this process by varying the limits and chose the ones that best meet our criteria by drawing histograms of the resulting distributions at ages 20, 40, 60, and 80.

To implement the method we used a Markov chain Monte Carlo (MCMC) algorithm. After estimating the posterior distributions of all parameters, we estimated the final meta-analysis penetrance curve. Specifically, for MCMC iteration t : (1) We computed $\kappa^{(t)} = a^{(t)} * b^{(t)}$ and $\lambda^{(t)} = c^{(t)} * d^{(t)}$ and (2) Used the Weibull($\kappa^{(t)}, \lambda^{(t)}$) cdf at ages 40, 50, 60, 70, and 80 as penetrance estimates at the t^{th} iteration. Finally, for each age, the mean of the penetrance values over all iterations are computed, which serves as the meta-analysis estimate. We also obtained credible intervals (CrI) using these posterior distributions of penetrances at each age.

We also investigated how sensitive our results are to the choice of fixed hyper-parameters. We explored two other sets of hyper-priors — one set allows for a wider range of penetrance values at each age compared to our chosen hyper-parameters as described above while the other would somewhat restrict the range of penetrance values. Both sets still ensure that the resulting penetrance values are in realistic ranges. The results of the sensitivity analysis showed that there were no substantial differences among penetrance values generated by different sets of hyper parameters. Please refer Ruberu et al. (2024) for a detailed description of the method.

Table S1: Details about studies included in the meta-analysis of BC penetrance for PALB2 mutations.

Index	Study	Country	Ancestry	# cases	# controls	Mutation Prevalence
1	Antoniou et al.	Multiple ^a	Not Reported	229	82	NA ^c
2	Erkko et al.	Finland	Not Reported	90	123	NA ^c
3	Rahman et al.	UK	Non UK ethnic groups were removed from cases. controls were 97% White	923	1084	0.005
4	Kurian et al.	USA	Western/Northern European 57% Central/Eastern European 14% Latin American/Caribbean 9% African 9% Native American 4% Asian 3% Ashkenazi 2% Near/Middle Eastern 1%	26384	69177	0.005
5	Momozawa et al.	Japan	Japanese ancestry	7051	11241	0.002
6	Díaz-Zabala et al.	USA	African American	1117	2169	0.004
7	Cybulski et al.	Poland	Not Reported	12529	4702	0.007
8	Dorling et al.	Multiple ^b	European Asian	47522	50475	0.003
9	Heikkinen et al.	Finland	Not Reported	1274	1079	0.004
10	Ahearn et al.	Ghana	African	871	1563	0.004
11	Zheng et al.	Nigeria	African	1136	997	0.005
12	Felix et al.	Brazil	White 19% African-descended 77% Other 4%	171	119	0.010

^a Families from 14 participating research centers across the world

^b Based on 30 studies in breast cancer association consortium (BCAC) unselected for family history.

^c Penetrance computation only use carriers

References

- Ahearn, T. U., Pal Choudhury, P., Derkach, A., Wiafe-Addai, B., Awuah, B., Yarney, J., et al. (2022). Breast cancer risk in women from Ghana carrying rare germline pathogenic mutations. *Cancer Epidemiology, Biomarkers & Prevention*, 31(8):1593–1601.
- Antoniou, A. C., Casadei, S., Heikkinen, T., Barrowdale, D., Pylkäs, K., Roberts, J., et al. (2014). Breast-cancer risk in families with mutations in PALB2. *The New England Journal of Medicine*, 371(6):497–506.
- Cybulski, C., Kluźniak, W., Huzarski, T., Wokołorczyk, D., Kashyap, A., Jakubowska, A., et al. (2015). Clinical outcomes in women with breast cancer and a PALB2 mutation: A prospective cohort analysis. *The Lancet Oncology*, 16(6):638–644.
- Díaz-Zabala, H., Guo, X., Ping, J., Wen, W., Shu, X.-O., Long, J., et al. (2022). Evaluating breast cancer predisposition genes in women of african ancestry. *Genetics in Medicine*, 24(7):1468–1475.
- Dorling, L., Carvalho, S., Allen, J., González-Neira, A., Luccarini, C., Wahlström, C., et al. (2021). Breast cancer risk genes-association analysis in more than 113,000 women. *The New England Journal of Medicine*, 384(5):428–439.
- Erkko, H., Dowty, J. G., Nikkilä, J., Syrjäkoski, K., Mannermaa, A., Pylkäs, K., et al. (2008). Penetrance analysis of the PALB2 c.1592delT founder mutation. *Clinical Cancer Research*, 14(14):4667–4671.
- Felix, G. E., Guindalini, R. S. C., Zheng, Y., Walsh, T., Sveen, E., Lopes, T. M. M., et al. (2022). Mutational spectrum of breast cancer susceptibility genes among women ascertained in a cancer risk clinic in Northeast Brazil. *Breast Cancer Research and Treatment*, 193(2):485–494.

- Heikkinen, T., Kärkkäinen, H., Aaltonen, K., Milne, R. L., Heikkilä, P., Aittomäki, K., et al. (2009). The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype. *Clinical Cancer Research*, 15(9):3214–3222.
- Kurian, A. W., Hughes, E., Handorf, E. A., Gutin, A., Allen, B., Hartman, A.-R., et al. (2017). Breast and ovarian cancer penetrance estimates derived from germline multiple-gene sequencing results in women. *JCO Precision Oncology*, 1:1–12.
- Marabelli, M., Cheng, S. C., and Parmigiani, G. (2016). Penetrance of ATM gene mutations in breast cancer: A meta-analysis of different measures of risk. *Genetic Epidemiology*, 40(5):425–431.
- Momozawa, Y., Iwasaki, Y., Parsons, M. T., Kamatani, Y., Takahashi, A., Tamura, C., et al. (2018). Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls. *Nature Communications*, 9(1):1–7.
- Rahman, N., Seal, S., Thompson, D., Kelly, P., Renwick, A., Elliott, A., et al. (2007). PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. *Nature Genetics*, 39(2):165–167.
- Ruberu, T. L. M., Braun, D., Parmigiani, G., and Biswas, S. (2024). Bayesian meta-analysis of penetrance for cancer risk. *Biometrics*. Accepted; discussants invited by the journal. arXiv:2304.01912 [STAT.ME].
- Zheng, Y., Walsh, T., Gulsuner, S., Casadei, S., Lee, M. K., Ogundiran, T. O., et al. (2018). Inherited breast cancer in Nigerian women. *Journal of Clinical Oncology*, 36(28):2820–2825.